Over the long-term it's one of the best-performing companies on the S&P/ ASX200 (ASX: XJO) and on April 16 Cochlear Ltd (ASX: COH) received a 'buy' rating from analysts at Goldman Sachs.
The stock got sold off relatively heavily recently on the back of concerns that a competitor named Advanced Bionics was taking significant market share from it in the key U.S. market due to a superior product.
However, news that Cochlear has launched a new hearing aid product named Nucleus Profile Plus that is compatible with other MRI products has the analysts at Goldmans confident that Cochlear might be back on track to winning market share and delivering strong top line growth.
This is a summary of Goldmans' research note: "COH commands a leading share (c.58%) in a structural growth market which is characterized by attractive demographics, relatively favourable pricing, substantial penetration upside and high barriers to entry."
You can't argue with that and the bullish attitude results in a $197 12-month share price target to mean there's plenty of upside for today's buyers if Goldmans in on the money.
